Re-screening for novel CD40-TRAF6 interaction inhibitors (TRAF-STOPs 2.0)


Funded period

2021 – 2021

Granted budget

€ 405,710

Indication

atherosclerosis

Therapeutic Principle

Drug

Principal Investigator

Dorothee Atzler, Christian Weber, Esther Lutgens (Hospital of Ludwig Maximilian University of Munich)

In this project, we aim to screen for new small molecule inhibitors, which can specifically block the inflammatory signals contributing to atherosclerosis as the dominating cause underlying cardiovascular disease, and may therefore serve as potential drug candidates for anti-inflammatory treatment.

striked outstriked out